

Fig. 1

Alpha diversity changes during the course of therapy




Fig. 2

Fig. 2





Fig. 3

Per patient bacterial phylum changes over time



4/25

Fig. 4




Fig. 5

Fig. 5A. Bile acid changes associated with ibezapolstat vs. vancomycin





Fig. 5B. Ratio of primary to secondary bile acids: Ibezapolstat vs. vancomycin



A higher number reflects a higher (unfavorable) proportion of primary to secondary bile acids

6/25
Fig. 6

Fig. 6A

A. Changes in Alpha-Diversity Through 10 Days of Therapy
by Shannon's Entropy






Fig. 6B




8/25

Fig. 6C



9/25


Fig. 6D




10/25

Fig. 7

Fig. 7A




11/25

Fig. 7B**B. Secondary Bile Acids**

12/25

Fig. 7C



13/25

Fig. 8





FIG. 9

Ibezapolstat Phase 2a Clinical Trial Results



EOT: End of Therapy

FIG. 10




FIG. 11




FIG. 12A




FIG. 12B






FIG. 13



C. Order



D. Family






FIG. 14.



22/25


FIG. 15A



23/25

FIG. 15B


B. Class



24/25

FIG. 15C

c. Order



25/25

FIG. 15D

D. Family

